drugset
drugset / Trial / NCT05511870

A Study of Etripamil in Healthy Subjects

NCT05511870 ↗

Phase 1 Completed 12 enrolled Corxel Pharmaceuticals Milestone Pharmaceuticals Inc. · collab
RandomizedParallel-groupDouble-blindBasic science

Summary

The objectives of the study are as below: Primary: ·To evaluate the pharmacokinetics (PK) of Etripamil in healthy adult Chinese subjects Secondary: * To evaluate the pharmacodynamics (PD) of Etripamil in healthy adult Chinese subjects * To evaluate the safety and tolerability of Etripamil in healthy adult Chinese subjects Exploratory: ·To evaluate the PK exposure-PD response relationship of etripamil in healthy adult Chinese subjects

Timeline

Start
2023-03-07
Primary completion
2023-03-26
Completion
2023-03-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Etripamil Small molecule 70 mg Intranasal

Indications

No indication recorded.